Trial · NCT00477451

Staccato Alprazolam in Panic Attack

NCT00477451, Phase 2, Completed, Alexza Pharmaceuticals, Inc.; results first posted 2017-06-16

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Staccato Alprazolam in Panic Attack. Trials, record NCT00477451. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00477451

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Staccato Alprazolam in Panic Attack
NCT number: NCT00477451
Status: Completed
Phases: Phase 2
Enrollment: 49 participants, actual
Lead sponsor: Alexza Pharmaceuticals, Inc.
Conditions: Treatment of Induced Panic Attack
Interventions: Inhaled placebo, Inhaled alprazolam 1 mg, Inhaled alprazolam 2 mg, IV doxapram
First posted: 2007-05-23
Last updated: 2017-06-16
Results first posted: 2017-06-16

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With Doxapram-induced Panic Attack	0 to 2 hours	doxapram-induced panic attack of sufficient intensity (DIPASI) defined as a 10 or greater increase from baseline in the acute panic inventory (API)
Primary	Duration of the Doxapram-induced Panic Attack	1 hr post-dose	Length of time from the doxapram injection to the time at which the acute panic inventory (API) value returns to within 10 points of the baseline API value. 0=never exceeded 0, 61=exceeded by more than 10 points still at end of assessment of 60 minutes. Thus each would have a duration whether or not they had a panic attack (DIPASI)
Secondary	Borg Max Change From Baseline	45 minutes	Subjects asked to "Point to the number (0 to 10) which matches how breathless you feel now" where 0=nothing at all to 10=very, very strong

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With Doxapram-induced Panic Attack	0 to 2 hours	RCT Population (N=40)	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Duration of the Doxapram-induced Panic Attack	1 hr post-dose	RCT Population (N=40)	minutes	MEAN
SECONDARY	Borg Max Change From Baseline	45 minutes	RCT Population (N=40)	units on a scale	MEAN

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Number of Participants With Doxapram-induced Panic Attack	RCT Placebo	14		Participants
Number of Participants With Doxapram-induced Panic Attack	RCT Alprazolam 1 mg	9		Participants
Duration of the Doxapram-induced Panic Attack	RCT Placebo	12.2	Standard Deviation 17.2	minutes
Duration of the Doxapram-induced Panic Attack	RCT Alprazolam 1 mg	9.25	Standard Deviation 14.1	minutes
Borg Max Change From Baseline	RCT Placebo	5.73	Standard Deviation 2.85	units on a scale
Borg Max Change From Baseline	RCT Alprazolam 1 mg	4.63	Standard Deviation 2.56	units on a scale

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	RCT Placebo	20
Overall Study	STARTED	RCT Alprazolam 1 mg	20
Overall Study	STARTED	Open Label Inhaled Alprazolam 1 mg	7
Overall Study	STARTED	Initial Inhaled Alprazolam 2 mg	2
Overall Study	COMPLETED	RCT Placebo	20
Overall Study	COMPLETED	RCT Alprazolam 1 mg	20
Overall Study	COMPLETED	Open Label Inhaled Alprazolam 1 mg	7
Overall Study	COMPLETED	Initial Inhaled Alprazolam 2 mg	2
Overall Study	NOT COMPLETED	RCT Placebo	0
Overall Study	NOT COMPLETED	RCT Alprazolam 1 mg	0

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events24

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Dysgeusia	Gastrointestinal disorders	RCT Placebo	1	20	1
other	Dysgeusia	Gastrointestinal disorders	RCT Alprazolam 1 mg	4	20	4
other	Dysgeusia	Gastrointestinal disorders	Open Label Inhaled Alprazolam 1 mg	0	7	0
other	Dysgeusia	Gastrointestinal disorders	Initial Inhaled Alprazolam 2 mg	0	2	0
other	Vomiting	Gastrointestinal disorders	RCT Placebo	0	20	0
other	Vomiting	Gastrointestinal disorders	RCT Alprazolam 1 mg	1	20	1
other	Vomiting	Gastrointestinal disorders	Open Label Inhaled Alprazolam 1 mg	0	7	0
other	Vomiting	Gastrointestinal disorders	Initial Inhaled Alprazolam 2 mg	1	2	1
other	Dizziness	Nervous system disorders	RCT Placebo	0	20	0
other	Dizziness	Nervous system disorders	RCT Alprazolam 1 mg	0	20	0

1 to 10 of 24Source ClinicalTrials.gov

See all 24 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	RCT Placebo	0	20
Total, all-cause mortality	RCT Alprazolam 1 mg	0	20
Total, all-cause mortality	Open Label Inhaled Alprazolam 1 mg	0	7
Total, all-cause mortality	Initial Inhaled Alprazolam 2 mg	0	2
Total, other adverse events	RCT Placebo	2	20
Total, other adverse events	RCT Alprazolam 1 mg	11	20
Total, other adverse events	Open Label Inhaled Alprazolam 1 mg	1	7
Total, other adverse events	Initial Inhaled Alprazolam 2 mg	1	2
Total, serious adverse events	RCT Placebo	0	20
Total, serious adverse events	RCT Alprazolam 1 mg	0	20

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
RCT Alprazolam 1 mg vs RCT Placebo: Number of Participants With Doxapram-induced Panic Attack

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00477451

GET https://conductscience.org/api/trials/v1/NCT00477451/events?page=2

API reference For AI assistants